Anti actin mab1501r

Brain tissues were obtained from the NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore, MD. For biochemical studies, hippocampus tissues from five AD cases and five non-demented control subjects were used (Table 1). The neuropathological diagnosis of AD was made using the Consortium to Establish a Registry for Alzheimer Disease criteria (Mirra et al., 1991 (link)). Brain tissues were homogenized in a buffer containing 50 mM HEPES, 100 mM NaCl, 1% (w/v) NP-40, and a mixture of protease inhibitors (Roche Molecular Biochemicals, Mannheim, Germany) and phosphatase inhibitors (Sigma, St. Louis, MO, U.S.A.). The supernatants were used for Western blot analysis with anti-PGC-1α (Choi et al., 2013 (link)), anti-actin (MAB1501R; Millipore, Billerica, MA, U.S.A.), and anti-PINK1 antibodies (LS-B3384; LSBio). Previously our study using Western blot analysis combined with siRNA treatment against PGC-1α showed that rabbit polyclonal PGC-1α (P-120) antibody raised against amino acids 1–120 can detect all potential isoforms of PGC-1α protein (Choi et al., 2013 (link)). Horseradish peroxidase-conjugated secondary antibodies were purchased from Pierce Biotechnology. Antibody binding was detected by using the SuperSignal chemiluminescence kit (Pierce Biotechnology, Rockford, IL, U.S.A.) and an Alpha Innotech imaging system.